FDA Dangles Trade Name Review Pilot, But Industry Still Looking For The Bait
Executive Summary
The success of FDA's pilot program for review of trade names will likely depend on the extent to which companies feel that taking on the burden will produce specific benefits for them
You may also be interested in...
FDA’s Trade Name Pilot Should Include Third-Party Reviews, Industry Says
Foreseeing battles over FDA and industry trade name discrepancies in a proposed pilot program, industry representatives are recommending that an independent, third-party review take place
FDA’s Trade Name Pilot Should Include Third-Party Reviews, Industry Says
Foreseeing battles over FDA and industry trade name discrepancies in a proposed pilot program, industry representatives are recommending that an independent, third-party review take place
Trade Name Review May Shift To Firms, But FDA Unclear Which Tests To Use
FDA is asking firms to use computerized methods and algorithms that can detect product name similarities as part of a pilot designed to expedite name review. The program, under which companies would generate their own data and submit it to FDA for review, will be discussed at a June 5-6 public meeting